Sponsors: Are Your Sites Ready for an FDA Inspection?
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While
Explore the state of DE&I in clinical research with survey insights on diversity plans, budgeting efforts, and progress in trial representation.
Discover how Parexel accelerated mRNA study startups with Advarra’s integrated IRB and IBC reviews, achieving rapid timelines and budget goals.
Ensuring the safe and secure transport of investigational products (IP) is a core part of biosafety. This critical task requires
The clinical trial startup process has seen significant shifts over the past five years: growth in decentralized trials, improved technology,
The clinical research industry is only becoming more complex and competitive as organizations are inundated with multiple trials and tight
Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for
Gene therapy research is at the forefront of a coming boom in the clinical setting. Understand the growth, risks, and regulatory requirements here.
When unexpected events occur during the conduct of a clinical trial, research personnel may wonder if the event is reportable,
Oncology trials face unique hurdles in innovation, enrollment, and endpoints, requiring strategic planning to address complex study demands and precision needs.